GenesisCare administers novel diagnostic agent Pylarify to first US patient
This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify (piflufolastat F 18), a novel radioactive diagnostic agent indicated for PSMA-PET imaging of lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and men with suspected recurrence based on an elevated PSA level. Brief commentary is also provided by Kishore K. Dass, MD, a radiation oncologist at GenesisCare in Boca Raton, Florida, where Bitterman received the treatment.
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial
February 11th 2022For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
